Efficacy of Rapamycin Therapy in the Women with Metastatic Breast Cancer in West Iran

Mehrdad Payandeh¹, Erkan Doğan², Masoud Sadeghi^{3, 4,} and Edris Sadeghi^{3, 4}

¹Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Department of Medical Oncology, Medical Faculty, Yuzuncu Yil University, Van, Turkey

³Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

⁴Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Cite this paper:
Mehrdad Payandeh, Erkan Doğan, Masoud Sadeghi and Edris Sadeghi. Efficacy of Rapamycin Therapy in the Women with Metastatic Breast Cancer in West Iran. American Journal of Cancer Prevention. 2015; 3(3):51-53. doi: 10.12691/ajcp-3-3-1

Abstract

Background: Mammalian target of rapamycin (mTOR) is one of the serine-threonine protein kinases and plays an important regulatory role in cell growth. Several randomized trials have shown that the use of mTOR inhibitors could improve patient outcome with hormone receptor-positive or Her2 positive breast cancer. The aim of study is to evaluation of efficacy of rapamycin therapy on the OS in metastatic breast cancer (mBC) patients in West Iran for the first time. Materials and Methods: Between of 2010 to 2014, sixty women with mBC referred to our Clinic. All of them after metastasis were treated with rapamycin (1 mg/day). Forty-three patients were treated for at least one year to three years (mean, 18 months) with rapamycin, that these patients were interred to our study. Results: The mean age for the patients at diagnosis of BC was 42 years (±9.9), 100% women. All of the patients had metastasis. For comparison of survival, we divide patients to 3 groups. Group 1: Patients with ER, PR positive and Her2 negative, Group 2: Patients with ER, PR and Her2 positive and Group 3: Patients with ER, PR and Her2 negative. The 5-year overall survival for mBC patients in group 1 was 93.3%, group 2 was 42.8% and group 3 was 72.7%. Conclusions: Rapamycin combination to hormone therapy increases the OS in the patients with mBC, but Rapamycin combination to trastizumab therapy reduces the OS.

Keywords:
metastatic breast cancer overall survival rapamycin

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Payandeh M, Sadeghi E, Sadeghi M, Eskandar AM. Different Presentation of Treatment in Carcinomatous Meningitis of Breast Cancer: Report of 3 Cases, American Journal of Cancer Prevention, 3 (1), 4-7, 2015.
[2]	Payandeh M, Sadeghi M, Fekri A, Sadeghi E. P53 mutation compared with Ki67 marker in metastasis of breast cancer in western Iran, Journal of Solid Tumors, 4 (3), 4-9,2014.
[3]	Hasson SP, Rubinek T, Ryvo L, Wolf I. Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway, Breast Care (Basel),8 (4), 248-55,2013.
[4]	Barnett CM. Everolimus: targeted therapy on the horizon for the treatment of breast cancer, Pharmacotherapy, 32, 383-396, 2012.
[5]	Seto B. Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer, Clin Transl Med, 1 (1), 29, 2012.
[6]	Payandeh M, Khodarahmi R, Sadeghi M, Sadeghi E. Appearance of Acute Myelogenous Leukemia (AML) in a Patient with Breast Cancer after Adjuvant Chemotherapy: Case Report and Review of the Literature, Iran J Cancer Prev, 8 (2), 125-8, 2015.
[7]	Payandeh M, Sadeghi M, Sadeghi E, koohian AK. Comparison of IHC, FISH, ER and PR in Breast Cancer in Western Iran, American Journal of Cancer Prevention, 2 (2), 37-41, 2014.
[8]	Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344 (11), 783-792, 2001.
[9]	Hu A, Sun M, Yan D, Chen K. Clinical significance of mTOR and eIF4E expression in invasive ductal carcinoma, Tumori, 100 (5), 541-6, 2014.
[10]	Vicier C, Dieci MV, Arnedos M, Delaloge S, Viens P, Andre F. Clinical development of mTOR inhibitors in breast cancer, Breast Cancer Res, 16 (1), 203, 2014.
[11]	Acevedo-Gadea C, Hatzis C, Chung G, Fishbach N, Lezon-Geyda K, Zelterman D, et al. Rapamycin and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy, Breast Cancer Res Treat, 150 (1), 157-67, 2015.
[12]	Vicier C, Dieci MV, Arnedos M, Delaloge S, Viens P, Andre F. Clinical development of mTOR inhibitors in breast cancer, Breast Cancer Res, 16 (1), 203, 2014.
[13]	Zeng Q, Yang Z, Gao YJ, Yuan H, Cui K, Shi Y, Wang H, Huang X, Wong ST, Wang Y, Kesari S, Ji RR, Xu X. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study, Eur J Cancer, 46 (6), 1132-43, 2010.
[14]	Chang SB, Miron P, Miron A, Iglehart JD. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells, J Surg Res, 138 (1), 37-44, 2007.
[15]	Ciruelos E, Cortes-Funes H, Ghanem I, Manso L, Arteaga C. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer, Anticancer Drugs, 24 (8), 769-80, 2013.